Does underdosing really explain why retatrutide 'doesn't work'?

What did @dompando actually say?

Dom's core argument is simple: if you're taking Retatrutide and feeling nothing, you're probably underdosing. He recommends starting at "1 mg per week," then escalating to "1 mg every 3 to 4 days" if you don't feel what he calls "optic suppression" by day two or three. He frames nausea and complete appetite loss as overdosing, and positions the sweet spot as appetite reduction without feeling sick. He also plugs coaching services and upcoming peptide guides on his site. That's the pitch, wrapped in the language of personalized biohacking.

To his credit, he does acknowledge individual variability and uses the phrase "trial and error" rather than claiming a universal protocol. But the framing throughout treats subjective sensations, specifically whether you "feel" something, as the primary dosing signal. That's a meaningful problem, and we'll get into why.

Does the science back this up?

Retatrutide's clinical trial data is real and genuinely impressive, but it doesn't support self-directed dose escalation based on how you feel. The published Phase 2 trial (Jastreboff et al., 2023, New England Journal of Medicine) tested doses from 1 mg up to 12 mg weekly in a controlled setting with medical oversight, showing up to 17.5% weight loss at 24 weeks in the highest dose group.

That same trial also showed dose-dependent increases in nausea, vomiting, and diarrhea. Participants in the 12 mg group had notably higher GI adverse event rates than lower-dose groups. The trial used fixed escalation schedules, not sensation-based titration. There is no peer-reviewed evidence supporting the use of subjective feelings like appetite suppression intensity as a reliable proxy for therapeutic adequacy. GLP-1 and GIP receptor agonists, which Retatrutide activates alongside GLP receptor activity, work on pathways that don't always produce perceptible acute signals, especially early in treatment or at lower doses.

What did they get wrong (or right)?

Dom gets partial credit for one thing: slow titration is genuinely the recommended approach with GLP-1 class drugs. Every major clinical protocol for semaglutide and tirzepatide, the closest approved analogs, starts low and escalates gradually to reduce GI side effects. That principle is sound.

What he gets wrong is using "optic suppression" and subjective appetite changes as dosing benchmarks. This isn't how therapeutic windows are established. Tolerability and efficacy are not the same thing. A patient can feel appetite suppression at a subtherapeutic dose, or feel nothing at a clinically meaningful dose due to individual receptor sensitivity. His framing also implicitly encourages dose escalation beyond what any compounded or clinical source has validated for this specific peptide in non-trial populations. Retatrutide is not FDA-approved. Compounded versions have no standardized potency verification. Telling 93,000 viewers to escalate to "2 mg, so on and so forth" based on hunger cues is not a safety framework. It's a guess dressed up as expertise.

What should you actually know?

Retatrutide is a triple agonist, hitting GLP-1, GIP, and glucagon receptors simultaneously. That mechanism is distinct from semaglutide or tirzepatide, and the clinical data for it is early-stage. The Phase 2 Jastreboff 2023 trial is promising but not a basis for consumer self-dosing protocols. There is no Phase 3 data yet, and no FDA approval pathway has been completed.

Compounded Retatrutide sold through peptide vendors is not equivalent to trial-grade drug. Purity, concentration, and sterility are not guaranteed without independent third-party testing. The FDA has flagged compounded GLP-1 receptor agonists specifically for quality concerns in recent years.

• Dose escalation should be guided by a licensed prescriber, not sensation-based self-assessment.
• GI symptoms like nausea are real safety signals, not just overdosing inconveniences to titrate around casually.
• "Feeling nothing" does not confirm therapeutic failure. It may reflect normal receptor-level activity without perceptible acute effects.
• Anyone using compounded peptides should request a certificate of analysis from their supplier and loop in a physician familiar with metabolic medicine.

Bottom line

Dom's video is not dangerous in the way that, say, recommending a contraindicated stack would be. But it teaches viewers to use subjective hunger signals as a clinical dosing tool for an unapproved, compounded peptide with limited safety data outside controlled trials. That's a meaningful gap between what sounds reasonable on TikTok and what responsible prescribing actually looks like. The 93,000 people who watched this deserved a clearer statement that this approach requires medical oversight, not a coach with a peptide guide on their website.